Vivitrol Dosing and Pre-Injection Drug Screening for Alcohol Treatment
For adults completing alcohol detoxification, Vivitrol (extended-release naltrexone) is administered as 380 mg intramuscularly into the gluteal muscle every 4 weeks (monthly), and patients must be opioid-free for a minimum of 7–10 days before the first injection to prevent precipitated withdrawal. 1
Dosing Schedule
Standard Dosing:
- 380 mg deep intramuscular gluteal injection every 4 weeks (monthly) 1
- Alternate buttocks with each subsequent injection
- Must be administered by a healthcare provider using the customized needles provided in the carton (1½-inch or 2-inch needles depending on body habitus)
- No oral naltrexone pretreatment is required before initiating Vivitrol 1
Critical Pre-Treatment Requirements:
- Patients must be abstinent from alcohol at the time of initial administration 1
- Patients should be able to abstain from alcohol in an outpatient setting prior to initiation 1
- Minimum 7–10 days opioid-free is mandatory before first injection to avoid severe precipitated opioid withdrawal that may require hospitalization 1
Pre-Injection Drug Screening
Mandatory Opioid Screening:
The most critical pre-injection testing is urine drug screening for opioids to confirm the patient has been opioid-free for at least 7–10 days. This is essential because naltrexone is a pure opioid antagonist that will precipitate severe withdrawal in anyone with opioids in their system 1.
Key Testing Considerations:
- Standard enzyme-linked immunoassays may not detect hydrocodone, fentanyl, hydromorphone, oxycodone, or methadone reliably 2
- Consider gas chromatography or mass spectrometry for comprehensive opioid detection if there is any concern about recent opioid use 2
- False-negative results can occur from tampering, so clinical assessment remains important 2
Additional Baseline Testing:
- Liver function tests (LFTs) at baseline, then every 3–6 months, as naltrexone has been associated with hepatocellular injury at supratherapeutic doses 3
- This is particularly important since the patient has alcohol use disorder and may have underlying liver disease 4
Clinical Implementation Algorithm
Step 1: Confirm Eligibility
- Patient has completed alcohol detoxification
- Patient is not actively drinking
- Patient is opioid-free for ≥7–10 days (verify by history AND urine drug screen)
Step 2: Baseline Testing
- Comprehensive urine drug screen (preferably with confirmatory testing for synthetic opioids)
- Baseline liver function tests
- Assess for contraindications (current opioid use, acute hepatitis, liver failure)
Step 3: First Injection
- Administer 380 mg IM gluteal injection
- Provide psychosocial support (counseling is essential component) 1, 5
- Educate patient about overdose risk if they relapse to opioid use while on naltrexone
Step 4: Ongoing Management
- Monthly injections (every 4 weeks)
- Monitor LFTs every 3–6 months 3
- Continue psychosocial support throughout treatment 4
Critical Safety Warnings
Opioid Sensitivity: Patients on Vivitrol will have increased sensitivity to opioids if they attempt to use them. This creates significant overdose risk, particularly:
- When the next dose is due
- If a dose is missed
- After treatment discontinuation 1
Overdose Prevention: At each injection visit, discuss and ensure access to naloxone (opioid overdose reversal agent) for emergency use, as patients may relapse after treatment ends or miss doses 1.
Hepatotoxicity: Naltrexone is not recommended in patients with active alcoholic liver disease due to risk of hepatic injury 6. However, guidelines support its use in combination with counseling for alcohol dependence in those who achieve abstinence 4.
Evidence for Efficacy
The evidence strongly supports Vivitrol's effectiveness when patients are already abstinent. In the pivotal trial, among patients who were completely abstinent during the week prior to first injection, Vivitrol 380 mg produced greater reductions in drinking days and heavy drinking days compared to placebo 1. However, these benefits were not evident among patients who were actively drinking at treatment initiation 1, reinforcing the importance of achieving abstinence before starting treatment.
Treatment retention and adherence remain challenges—approximately 44% of patients complete all scheduled injections in real-world settings 7, though rates are higher in structured research settings. Combining Vivitrol with case management and psychosocial support significantly improves outcomes 8, 9.